Your browser doesn't support javascript.
loading
Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients.
Valle, M; Van der Speeten, K; Garofalo, A.
Affiliation
  • Valle M; Department of Surgical Oncology, Digestive Branch, Regina Elena National Cancer Institute, Rome, Italy.
J Surg Oncol ; 100(4): 331-4, 2009 Sep 15.
Article in En | MEDLINE | ID: mdl-19697441
ABSTRACT
Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ascites / Chemotherapy, Cancer, Regional Perfusion / Antineoplastic Combined Chemotherapy Protocols / Laparoscopy / Drug Resistance, Neoplasm / Neoplasms Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: J Surg Oncol Year: 2009 Type: Article Affiliation country: Italy
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ascites / Chemotherapy, Cancer, Regional Perfusion / Antineoplastic Combined Chemotherapy Protocols / Laparoscopy / Drug Resistance, Neoplasm / Neoplasms Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: J Surg Oncol Year: 2009 Type: Article Affiliation country: Italy